HomeCompareMRSN vs DVY

MRSN vs DVY: Dividend Comparison 2026

MRSN yields 6.88% · DVY yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRSN wins by $6.5K in total portfolio value
10 years
MRSN
MRSN
● Live price
6.88%
Share price
$29.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.5K
Annual income
$1,064.67
Full MRSN calculator →
DVY
DVY
● Live price
3.46%
Share price
$151.41
Annual div
$5.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.0K
Annual income
$432.91
Full DVY calculator →

Portfolio growth — MRSN vs DVY

📍 MRSN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRSNDVY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRSN + DVY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRSN pays
DVY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRSN
Annual income on $10K today (after 15% tax)
$584.59/yr
After 10yr DRIP, annual income (after tax)
$904.97/yr
DVY
Annual income on $10K today (after 15% tax)
$294.47/yr
After 10yr DRIP, annual income (after tax)
$367.97/yr
At 15% tax rate, MRSN beats the other by $537.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRSN + DVY for your $10,000?

MRSN: 50%DVY: 50%
100% DVY50/50100% MRSN
Portfolio after 10yr
$28.3K
Annual income
$748.79/yr
Blended yield
2.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRSN right now

MRSN
Analyst Ratings
11
Buy
8
Hold
Consensus: Buy
Price Target
$10.00
-65.6% upside vs current
Range: $3.00 — $17.00
Altman Z
-23.2
Piotroski
2/9
DVY
No analyst data
Altman Z
307.5
Piotroski
1/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRSN buys
0
DVY buys
0
No recent congressional trades found for MRSN or DVY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRSNDVY
Forward yield6.88%3.46%
Annual dividend / share$2.00$5.25
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$31.5K$25.0K
Annual income after 10y$1,064.67$432.91
Total dividends collected$8.8K$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MRSN vs DVY ($10,000, DRIP)

YearMRSN PortfolioMRSN Income/yrDVY PortfolioDVY Income/yrGap
1← crossover$11,388$687.76$11,046$346.43+$342.00MRSN
2$12,917$731.96$12,177$357.65+$740.00MRSN
3$14,597$775.93$13,398$368.47+$1.2KMRSN
4$16,438$819.50$14,715$378.89+$1.7KMRSN
5$18,451$862.49$16,134$388.90+$2.3KMRSN
6$20,648$904.79$17,662$398.51+$3.0KMRSN
7$23,039$946.25$19,306$407.71+$3.7KMRSN
8$25,639$986.78$21,074$416.50+$4.6KMRSN
9$28,460$1,026.28$22,974$424.90+$5.5KMRSN
10$31,517$1,064.67$25,015$432.91+$6.5KMRSN

MRSN vs DVY: Complete Analysis 2026

MRSNStock

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Full MRSN Calculator →

DVYETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →
📬

Get this MRSN vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRSN vs SCHDMRSN vs JEPIMRSN vs OMRSN vs KOMRSN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.